PoD-TPI: Probability-of-Decision Toxicity Probability Interval Design to Accelerate Phase I Trials

被引:7
|
作者
Zhou, Tianjian [1 ]
Guo, Wentian [2 ]
Ji, Yuan [1 ]
机构
[1] Univ Chicago, Dept Publ Hlth Sci, Chicago, IL 60637 USA
[2] Laiya Consulting Inc, Chicago, IL USA
关键词
Clinical trial design; Decision theory; Dose finding; Late-onset toxicity; Maximum tolerated dose; CLINICAL-TRIALS; PEDIATRIC-PATIENTS; RAZOR;
D O I
10.1007/s12561-019-09264-0
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Cohort-based enrollment can slow down dose-finding trials since the outcomes of the previous cohort must be fully evaluated before the next cohort can be enrolled. This results in frequent suspension of patient enrollment. The issue is exacerbated in recent immune oncology trials where toxicity outcomes can take a long time to observe. We propose a novel phase I design, the probability-of-decision toxicity probability interval (PoD-TPI) design, to accelerate phase I trials. PoD-TPI enables dose assignment in real time in the presence of pending toxicity outcomes. With uncertain outcomes, the dose assignment decisions are treated as a random variable, and we calculate the posterior distribution of the decisions. The posterior distribution reflects the variability in the pending outcomes and allows a direct and intuitive evaluation of the confidence of all possible decisions. Optimal decisions are calculated based on 0-1 loss, and extra safety rules are constructed to enforce sufficient protection from exposing patients to risky doses. A new and useful feature of PoD-TPI is that it allows investigators and regulators to balance the trade-off between enrollment speed and making risky decisions by tuning a pair of intuitive design parameters. Through numerical studies, we evaluate the operating characteristics of PoD-TPI and demonstrate that PoD-TPI shortens trial duration and maintains trial safety and efficiency compared to existing time-to-event designs.
引用
收藏
页码:124 / 145
页数:22
相关论文
共 50 条
  • [1] PoD-TPI: Probability-of-Decision Toxicity Probability Interval Design to Accelerate Phase I Trials
    Tianjian Zhou
    Wentian Guo
    Yuan Ji
    [J]. Statistics in Biosciences, 2020, 12 : 124 - 145
  • [2] Probability-of-decision interval 3+3 (POD-i3+3) design for phase I dose finding trials with late-onset toxicity
    Xu, Zichun
    Lin, Xiaolei
    [J]. STATISTICAL METHODS IN MEDICAL RESEARCH, 2022, 31 (03) : 534 - 548
  • [3] R-TPI: rolling toxicity probability interval design to shorten the duration and maintain safety of phase I trials
    Guo, Wentian
    Ji, Yuan
    Li, Daniel
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2019, 29 (03) : 411 - 424
  • [4] Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials
    Yan, Fangrong
    Mandrekar, Sumithra J.
    Yuan, Ying
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (15) : 3994 - 4003
  • [5] qTPI: A quasi-toxicity probability interval design for phase I trials with multiple-grade toxicities
    Ling, Haodong
    Shi, Haolun
    Yuan, Nan
    Ji, Yuan
    Lin, Xiaolei
    [J]. STATISTICAL METHODS IN MEDICAL RESEARCH, 2023, 32 (07) : 1389 - 1402
  • [6] Toxicity and Efficacy Probability Interval Design for Phase I Adoptive Cell Therapy Dose-Finding Clinical Trials
    Li, Daniel H.
    Whitmore, James B.
    Guo, Wentian
    Ji, Yuan
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (01) : 13 - 20
  • [7] uTPI: A utility-based toxicity probability interval design for phase I/II dose-finding trials
    Shi, Haolun
    Cao, Jiguo
    Yuan, Ying
    Lin, Ruitao
    [J]. STATISTICS IN MEDICINE, 2021, 40 (11) : 2626 - 2649
  • [8] Modified Toxicity Probability Interval Design: A Safer and More Reliable Method Than the 3+3 Design for Practical Phase I Trials
    Ji, Yuan
    Wang, Sue-Jane
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (14) : 1785 - +
  • [9] Toxicity and efficacy probability intervals design for phase I dose-finding in oncology trials
    Li, Daniel H.
    Whitmore, Jim
    Ji, Yuan
    [J]. CANCER RESEARCH, 2016, 76
  • [10] Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials
    Yuan, Ying
    Lin, Ruitao
    Li, Daniel
    Nie, Lei
    Warren, Katherine E.
    [J]. CLINICAL CANCER RESEARCH, 2018, 24 (20) : 4921 - 4930